The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Gong, J.-H., Maki, G., & Klingemann, H.-G. (1994) · PubMed · Cited by 723
Self-citationRecruitment of Tyrosine Phosphatase HCP by the Killer Cell Inhibitory Receptor
Burshtyn, D. N., Scharenberg, A. M., Wagtmann, N., Rajagopalan, S., Berrada, K., Yi, T., Kinet, J.-P., & Long, E. O. (1996) · Immunity · doi:10.1016/s1074-7613(00)80300-3 · Cited by 613
Protection from Natural Killer Cell-Mediated Lysis by HLA-G Expression on Target Cells
Pazmany, L., Mandelboim, O., Valés-Gómez, M., Davis, D. M., Reyburn, H. T., & Strominger, J. L. (1996) · Science · doi:10.1126/science.274.5288.792 · Cited by 497
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Self-citationArai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
Self-citationSchönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Self-citationSerial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic Antibodies
Bhat, R., & Watzl, C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000326 · Cited by 286
KIR2DL4 (CD158d), an NK Cell-Activating Receptor with Inhibitory Potential
Faure, M., & Long, E. O. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6208 · Cited by 268
Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92
Tonn, T., Becker, S., Esser, R., Schwabe, D., & Seifried, E. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/15258160152509145 · Cited by 267
Self-citationUherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Self-citationFactors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92
Maki, G., Klingemann, H.-G., Martinson, J. A., & Tam, Y. K. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/152581601750288975 · Cited by 262
Self-citationCooley, S., Xiao, F., Pitt, M., Gleason, M., McCullar, V., Bergemann, T. L., McQueen, K. L., Guethlein, L. A., Parham, P., & Miller, J. S. (2007) · Blood · doi:10.1182/blood-2006-07-036228 · Cited by 226
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Self-citationTam, Y. K., Maki, G., Miyagawa, B., Hennemann, B., Tonn, T., & Klingemann, H.-G. (1999) · Human Gene Therapy · doi:10.1089/10430349950018030 · Cited by 203
Self-citationBoissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Self-citationYagita, M., Huang, C., Umehara, H., Matsuo, Y., Tabata, R., Miyake, M., Konaka, Y., & Takatsuki, K. (2000) · Leukemia · doi:10.1038/sj.leu.2401769 · Cited by 186
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Self-citationAntileukemia activity of a natural killer cell line against human leukemias.
Yan, Y., Steinherz, P. G., Klingemann, H., Dennig, D., Childs, B. H., McGuirk, J. P., & O’Reilly, R. J. (1998) · PubMed · Cited by 167
Self-citationDaldrup-Link, H. E., Meier, R., Rudelius, M., Piontek, G., Piert, M., Metz, S., Settles, M., Uherek, C., Wels, W., Schlegel, J., et al. (2005) · European Radiology · doi:10.1007/s00330-004-2526-7 · Cited by 167
Self-citationBoissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Self-citationSignatures of Human NK Cell Development and Terminal Differentiation
Luetke-Eversloh, M. V., Killig, M., & Romagnani, C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00499 · Cited by 154
Tarn, Y. K., Martinson, J., Doligosa, K., & Klingernann, H.-G. (2003) · Cytotherapy · doi:10.1080/14653240310001523 · Cited by 149
Boissel, L., Betancur, M., Lu, W., Wels, W. S., Marino, T., Etten, R. A. V., & Klingemann, H. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.634048 · Cited by 146
Self-citationTam, Y. K., Miyagawa, B., HO, V. C., & Klingemann, H.-G. (1999) · Journal of Hematotherapy · doi:10.1089/106161299320316 · Cited by 133
Self-citationImaging burst kinetics and spatial coordination during serial killing by single natural killer cells
Choi, P. J., & Mitchison, T. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221312110 · Cited by 133
Ex vivo expansion of natural killer cells for clinical applications
Klingemann, H.-G., & Martinson, J. (2004) · Cytotherapy · doi:10.1080/14653240310004548 · Cited by 117
Self-citationBringing natural killer cells to the clinic: ex vivo manipulation
Childs, R. W., & Berg, M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.234 · Cited by 110
KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck, G., Branch, D., Smyth, M., Miller, R. G., Vergidis, J., Fahim, S., & Keating, A. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.06.024 · Cited by 106
Self-citationTherapeutic applications: natural killer cells in the clinic
Miller, J. S. (2013) · Hematology · doi:10.1182/asheducation-2013.1.247 · Cited by 96
Romanski, A., Bug, G., Becker, S., Kampfmann, M., Seifried, E., Hoelzer, D. F., Ottmann, O. G., & Tonn, T. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.11.006 · Cited by 93
Self-citationSwift, B. E., Williams, B. A., Kosaka, Y., Wang, X.-H., Medin, J. A., Viswanathan, S., Martínez‐López, J., & Keating, A. (2012) · Haematologica · doi:10.3324/haematol.2011.054254 · Cited by 74
Oncolytic Virotherapy for Hematological Malignancies
Bais, S., Bartee, E., Rahman, M. M., McFadden, G., & Cogle, C. R. (2011) · Advances in Virology · doi:10.1155/2012/186512 · Cited by 40
Cellular therapy of cancer with natural killer cells—where do we stand?
Klingemann, H. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.03.011 · Cited by 37
Self-citationSuck, G., & Koh, M. (2010) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(10)50024-4 · Cited by 35
Self-citationSuck, G., Branch, D. R., & Keating, A. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000600649653 · Cited by 34
Self-citationConstitutively polarized granules prime KHYG-1 NK cells
Suck, G., Branch, D. R., Aravena, P., Mathieson, M., Helke, S., & Keating, A. (2006) · International Immunology · doi:10.1093/intimm/dxl071 · Cited by 31
Self-citationImpact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma
Heidenreich, S., zu Eulenburg, C., Hildebrandt, Y., Stübig, T., Sierich, H., Badbaran, A., EIERMANN, T. H., Binder, T. M. C., & Kröger, N. M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/652130 · Cited by 27
Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia
Maki, G., Tam, Y. K., Berkahn, L., & Hg, K. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704117 · Cited by 23
Genetically Modified T Cells for the Treatment of Malignant Disease
Wieczorek, A., & Uharek, L. (2013) · Transfusion Medicine and Hemotherapy · doi:10.1159/000357163 · Cited by 23
Shipping of therapeutic somatic cell products
Whiteside, T. L., Griffin, D. L., Stanson, J., Gooding, W. E., McKenna, D. H., Sumstad, D., Kadidlo, D. M., Gee, A. P., Durett, A. G., Lindblad, R., et al. (2010) · Cytotherapy · doi:10.3109/14653249.2010.506507 · Cited by 23
Reid, G. S. D., Bharya, S., Klingemann, H.-G., & Schultz, K. R. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01919.x · Cited by 22
Self-citationYahng, S., Yoon, J., Shin, S., Lee, S., Cho, B., Eom, K., Kim, Y., Lee, S., Kim, H., Min, C., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12664 · Cited by 11
KHYG-1 and NK-92 represent different subtypes of LFA-1-mediated NK cell adhesiveness
Suck, G., Tan, S.-M., Chu, S., Niam, M., Vararattanavech, A., Lim, T. J., & Koh, M. B. C. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e230 · Cited by 8
Self-citation
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 453
Immunometabolism and natural killer cell responses
O’Brien, K. L., & Finlay, D. K. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0139-2 · Cited by 435
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01205 · Cited by 398
Metadata
- Authors
- Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2015-11-11
- Volume
- 65
- Issue
- 4
- Pages
- 485-492
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2138076568
- Cited by
- 328
- References
- 44
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.